Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “hold” rating reissued by research analysts at BTIG Research in a research note issued to investors on Tuesday.
A number of other research firms also recently weighed in on REGN. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, October 16th. Canaccord Genuity reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, October 16th. Barclays downgraded shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and dropped their price target for the stock from $450.00 to $395.00 in a research note on Friday, October 20th. Guggenheim reaffirmed a “buy” rating and issued a $540.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. Finally, BMO Capital Markets dropped their price target on shares of Regeneron Pharmaceuticals from $491.00 to $479.00 and set a “market perform” rating on the stock in a research note on Thursday, November 9th. Four investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Hold” and an average price target of $463.19.
Regeneron Pharmaceuticals (NASDAQ REGN) opened at $342.67 on Tuesday. Regeneron Pharmaceuticals has a one year low of $314.99 and a one year high of $543.55. The company has a quick ratio of 3.18, a current ratio of 3.82 and a debt-to-equity ratio of 0.11. The firm has a market cap of $36,140.33, a price-to-earnings ratio of 33.20, a PEG ratio of 1.27 and a beta of 1.47.
Large investors have recently modified their holdings of the stock. Shell Asset Management Co. boosted its holdings in Regeneron Pharmaceuticals by 24.1% in the third quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock worth $5,565,000 after purchasing an additional 2,999 shares in the last quarter. DnB Asset Management AS bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $9,136,000. Northpointe Capital LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at about $2,089,000. Cubist Systematic Strategies LLC boosted its holdings in Regeneron Pharmaceuticals by 176.1% during the second quarter. Cubist Systematic Strategies LLC now owns 671 shares of the biopharmaceutical company’s stock valued at $330,000 after acquiring an additional 428 shares during the period. Finally, Griffin Asset Management Inc. bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at about $1,579,000. Hedge funds and other institutional investors own 65.89% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “BTIG Research Reaffirms “Hold” Rating for Regeneron Pharmaceuticals (REGN)” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2018/02/13/btig-research-reaffirms-hold-rating-for-regeneron-pharmaceuticals-regn.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.